Status: Not yet recruiting
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Provincial People's HospitalUpdated: Mar 4, 2025Locations: 1
Eligibility criteria
Age 18-75 years (including boundary values), male or female. [+4]
Need to breastfeed the baby or have fertility needs； [+5]